Stacy Ann  Coen net worth and biography

Stacy Coen Biography and Net Worth

SVP of ImmunoGen
Stacy A. Coen is the Sr. VP & Chief Bus. Officer at Immunogen.

What is Stacy Ann Coen's net worth?

The estimated net worth of Stacy Ann Coen is at least $593,673.96 as of November 17th, 2023. Ms. Coen owns 36,966 shares of ImmunoGen stock worth more than $593,674 as of November 29th. This net worth evaluation does not reflect any other assets that Ms. Coen may own. Learn More about Stacy Ann Coen's net worth.

How do I contact Stacy Ann Coen?

The corporate mailing address for Ms. Coen and other ImmunoGen executives is 830 WINTER ST, WALTHAM MA, 02451. ImmunoGen can also be reached via phone at (781) 895-0600 and via email at [email protected]. Learn More on Stacy Ann Coen's contact information.

Has Stacy Ann Coen been buying or selling shares of ImmunoGen?

Over the course of the past ninety days, Stacy Ann Coen has sold $1,255,479.15 of ImmunoGen stock. Most recently, Stacy Ann Coen sold 78,223 shares of the business's stock in a transaction on Friday, November 17th. The shares were sold at an average price of $16.05, for a transaction totalling $1,255,479.15. Following the completion of the sale, the senior vice president now directly owns 36,966 shares of the company's stock, valued at $593,304.30. Learn More on Stacy Ann Coen's trading history.

Who are ImmunoGen's active insiders?

ImmunoGen's insider roster includes Susan Altschuller (Sr. VP & CFO ), Stacy Coen (SVP), Mark Enyedy (Pres), Mark Enyedy (CEO), Renee Lentini (Insider), and Theresa Wingrove (SVP). Learn More on ImmunoGen's active insiders.

Are insiders buying or selling shares of ImmunoGen?

During the last year, insiders at the biotechnology company sold shares 11 times. They sold a total of 2,221,095 shares worth more than $35,723,707.24. The most recent insider tranaction occured on November, 17th when SVP Stacy Ann Coen sold 78,223 shares worth more than $1,255,479.15. Insiders at ImmunoGen own 5.1% of the company. Learn More about insider trades at ImmunoGen.

Information on this page was last updated on 11/17/2023.

Stacy Ann Coen Insider Trading History at ImmunoGen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2023Sell78,223$16.05$1,255,479.1536,966View SEC Filing Icon  
8/9/2023Sell100,210$14.20$1,422,982.0010,960View SEC Filing Icon  
8/4/2023Sell80,326$17.05$1,369,558.3010,960View SEC Filing Icon  
8/2/2023Sell4,255$18.12$77,100.6010,960View SEC Filing Icon  
See Full Table

Stacy Ann Coen Buying and Selling Activity at ImmunoGen

This chart shows Stacy Ann Coen's buying and selling at ImmunoGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ImmunoGen Company Overview

ImmunoGen logo
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $16.06
Low: $15.88
High: $16.69

50 Day Range

MA: $15.13
Low: $12.46
High: $16.29

2 Week Range

Now: $16.06
Low: $3.61
High: $20.69


4,622,960 shs

Average Volume

5,268,847 shs

Market Capitalization

$4.28 billion

P/E Ratio


Dividend Yield